OverviewSuggest Edit

Esperion Therapeutics is a pharmaceutical company. It specializes in developing and commercializing oral, low‑density lipoprotein cholesterol (LDL-C) therapies for patients with hypercholesterolemia.

TypePublic
Founded2008
HQAnn Arbor, MI, US
Websiteesperion.com
Employee Ratings3.5
Overall CultureF

Latest Updates

Employees (est.) (Dec 2019)193(+154%)
Job Openings6
Revenue (FY, 2020)$227.5 M(+54%)
Share Price (Sept 2021)$12.1(+7%)
Cybersecurity ratingAMore

Key People/Management at Esperion Therapeutics

Richard Bartram

Richard Bartram

CFO
Ashley Hall

Ashley Hall

Chief Development Officer
Ken Fiorelli

Ken Fiorelli

Chief Technical Operations Officer
Sheldon Koenig

Sheldon Koenig

President, CEO
Show more

Esperion Therapeutics Office Locations

Esperion Therapeutics has an office in Ann Arbor
Ann Arbor, MI, US (HQ)
3891 Ranchero Dr
Show all (1)

Esperion Therapeutics Financials and Metrics

Esperion Therapeutics Revenue

Esperion Therapeutics's revenue was reported to be $227.55 m in FY, 2020 which is a 53.4% increase from the previous period.
USD

Revenue (Q2, 2021)

40.7m

Gross profit (Q2, 2021)

38.9m

Gross profit margin (Q2, 2021), %

95.6%

Net income (Q2, 2021)

(43.7m)

EBIT (Q2, 2021)

(32.5m)

Market capitalization (16-Sept-2021)

340.8m

Closing stock price (16-Sept-2021)

12.1

Cash (30-Jun-2021)

219.2m

EV

398.0m
Esperion Therapeutics's current market capitalization is $340.8 m.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

148.4m227.5m

Revenue growth, %

53%

Cost of goods sold

2.4m

Gross profit

225.2m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Revenue

145.4m982.0k981.0k1.8m212.2m3.3m8.0m40.7m

Cost of goods sold

31.0k398.0k275.0k1.8m1.8m

Gross profit

1.8m211.8m3.1m6.2m38.9m

Gross profit Margin, %

98%100%92%78%96%
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

37.0m166.1m305.0m

Prepaid Expenses

6.6m10.0m24.8m

Inventories

16.1m

Current Assets

142.6m211.7m345.9m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Cash

174.8m274.3m212.0m149.4m298.5m215.7m217.9m219.2m

Accounts Receivable

21.9m

Prepaid Expenses

5.3m4.8m8.4m12.5m12.4m18.0m34.6m10.4m

Inventories

1.8m8.2m9.1m20.0m23.7m
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(201.8m)(97.2m)(143.6m)

Depreciation and Amortization

265.0k(319.0k)547.0k

Inventories

(16.1m)

Accounts Payable

24.4m(16.1m)23.1m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Net Income

87.4m33.2m(35.2m)(78.2m)46.4m(39.1m)(90.9m)(134.6m)

Depreciation and Amortization

71.0k126.0k218.0k106.0k224.0k387.0k153.0k306.0k

Inventories

(1.8m)(8.2m)(9.1m)(3.9m)(7.6m)

Accounts Payable

(11.5m)(16.7m)(21.2m)(13.6m)921.0k(11.3m)(21.6m)(22.2m)
USDFY, 2018

Financial Leverage

1.8 x

P/E Ratio

(6.1)
Show all financial metrics

Esperion Therapeutics Operating Metrics

Esperion Therapeutics's Prescriptions Filled was reported to be 3.3 k in FY, 2020.
FY, 2020Q1, 2021Q2, 2021

Patients Served to Date

35 k35 k47.8 k

Prescriptions Filled

3.3 k
Show all operating metrics

Esperion Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Esperion Therapeutics Online and Social Media Presence

Embed Graph

Esperion Therapeutics Company Culture

  • Overall Culture

    F

    28/100

  • CEO Rating

    F

    18/100

  • Compensation

    F

    40/100

  • Diversity

    F

    23/100

Learn more on Comparably

Esperion Therapeutics News and Updates

Association of Black Cardiologists Distributes 20,000 N95 Masks to Practices Serving Vulnerable Communities Thanks to Donation from Esperion Therapeutics

WASHINGTON, March 15, 2021 /PRNewswire/ -- One year into the pandemic and the dearth of N95 face masks for healthcare workers continues, with practices and facilities that serve some of the most vulnerable communities still unable to obtain adequate supplies.[1] So when biopharmaceutical...

Thinking about trading options or stock in Duke Energy, Esperion Therapeutics, Expedia, MSCI Inc, or Walmart?

NEW YORK, Feb. 18, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DUK, ESPR, EXPE, MSCI, and WMT. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

Moore Kuehn Encourages Esperion Therapeutics, Inc. Investors to Contact Law Firm for Possible Claims Against Officers and Directors

NEW YORK, April 24, 2019 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City, is investigating whether certain officers and directors of Esperion Therapeutics, Inc. (NASDAQ: ESPR) breached their fiduciary duties to shareholders....

Esperion Therapeutics Blogs

ESPERION Reports First Quarter 2021 Financial Results and Provides Company Update

ESPERION Reports First Quarter 2021 Financial Results and Provides Company Update Content Import Tue, 05/04/2021 - 16:01 ESPERION Reports First Quarter 2021 Financial Results and Provides Company Update May 4, 2021 This release is a backfill from a News Wire …

Esperion Secures $50 Million Funding from Oberland Capital

ANN ARBOR, Mich., April 26, 2021 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced that an investor group led by Oberland Capital Management LLC (Oberland Capital) agreed to provide the third and final tranche of funding under the revenue-based funding agreement totaling $50

Esperion to Report First Quarter 2021 Financial Results May 4, 2021

Esperion to Report First Quarter 2021 Financial Results May 4, 2021 Content Import Mon, 04/12/2021 - 16:01 Esperion to Report First Quarter 2021 Financial Results May 4, 2021 Apr 12, 2021 This release is a backfill from a News Wire Genera…

ESPERION Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update

Fourth Quarter 2020 U.S. Product Revenue of $8.2 Million, Approximately 150 Percent Increase Compared to the Third Quarter Over 21,000 Patients on NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Tablets in the U.S. CLEAR Outcomes Study Design Highlighted in The American

ESPERION Reports Third Quarter 2020 Financial Results and Provides Company Update

ESPERION Reports Third Quarter 2020 Financial Results and Provides Company Update Content Import Mon, 11/02/2020 - 16:01 ESPERION Reports Third Quarter 2020 Financial Results and Provides Company Update Nov 2, 2020 This release is a backfill from a News Wire …

NEXLETOL® (bempedoic acid) Tablets Highlighted in EAS 2020 Presentation of Analysis Demonstrating Significant Cholesterol Lowering in People with Familial Hypercholesterolemia

- NEXLETOL® exhibited a 22% mean reduction in LDL-C levels in patients with Heterozygous Familial Hypercholesterolemia at week-12 - ANN ARBOR, Mich., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced results of pooled data from two of the company’s Phase 3 trials were
Show more

Esperion Therapeutics Frequently Asked Questions

  • When was Esperion Therapeutics founded?

    Esperion Therapeutics was founded in 2008.

  • Who are Esperion Therapeutics key executives?

    Esperion Therapeutics's key executives are Richard Bartram, Ashley Hall and Ken Fiorelli.

  • How many employees does Esperion Therapeutics have?

    Esperion Therapeutics has 193 employees.

  • What is Esperion Therapeutics revenue?

    Latest Esperion Therapeutics annual revenue is $227.5 m.

  • What is Esperion Therapeutics revenue per employee?

    Latest Esperion Therapeutics revenue per employee is $1.2 m.

  • Who are Esperion Therapeutics competitors?

    Competitors of Esperion Therapeutics include CSPC Pharmaceutical Group, Macleods Pharmaceuticals and Sandoz.

  • Where is Esperion Therapeutics headquarters?

    Esperion Therapeutics headquarters is located at 3891 Ranchero Dr, Ann Arbor.

  • Where are Esperion Therapeutics offices?

    Esperion Therapeutics has an office in Ann Arbor.

  • How many offices does Esperion Therapeutics have?

    Esperion Therapeutics has 1 office.